AC Immune S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACIU research report →
Range $7 – $7
Price Chart
About the company
AC Immune S. A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools.
- CEO
- Martin Zügel
- IPO
- 2016
- Employees
- 106
- HQ
- Lausanne, VD, CH
Get TickerSpark's AI analysis on ACIU
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $198.46M
- P/E
- -4.09
- Fwd P/E
- 7.49
- PEG
- -0.07
- P/S
- 8.42
- P/B
- 6.05
- EV/EBITDA
- -4.32
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -190.78%
- Net Margin
- -181.94%
- ROE
- -104.05%
- ROIC
- -89.17%
Latest fiscal year · YoY change
- Revenue
- $3.57M-86.9%
- Gross Profit
- $3.57M+110.1%
- Op Income
- $-68,863,000
- Net Income
- $-70,447,000-38.4%
- EPS
- $-0.70-37.3%
- OCF Growth
- -200.5%
- FCF Growth
- -202.7%
- 52W High
- $3.90
- 52W Low
- $1.93
- 50D MA
- $2.43
- 200D MA
- $2.63
- Beta
- 1.61
- RSI (14)
- 36
- Avg Volume
- 198.81K
No earnings-call transcripts are available for ACIU yet.
- Free Float
- 61.5%
- Shares Outstanding
- 101.77M
- Float Shares
- 62.56M
of shares held by institutions
47 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bvf Inc/Il | 19.82M | 0 |
| Wells Fargo & Company/Mn | 1.00M | ▼ 243 |
| Renaissance Technologies LLC | 843.17K | ▲ 3.04K |
| Millennium Management LLC | 773.59K | ▼ 19.06K |
| Blackrock, Inc. | 562.38K | ▲ 43.10K |
| Dimensional Fund Advisors LP | 349.35K | ▲ 9.27K |
| Arrowstreet Capital, Limited Partnership | 225.07K | ▼ 7.88K |
| Citadel Advisors LLC | 207.61K | ▼ 59.63K |
| Two Sigma Investments, LP | 102.83K | ▲ 63.73K |
| Ubs Group AG | 70.93K | ▼ 14.69K |
| Geode Capital Management, LLC | 69.85K | ▲ 8.00K |
| Susquehanna International Group, Llp | 53.37K | ▼ 35.89K |
Held by 21 ETFs
Biggest fund positions in ACIU by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 10, 27 | Graney Thomas | other | 0 |
| Oct 2, 26 | Graney Thomas | other | 0 |
| Jun 10, 27 | Graney Thomas | other | 0 |
| Oct 2, 26 | Graney Thomas | other | 0 |
| Jun 11, 26 | Twyman Roy Ervin | other | 16,568 |
| Jun 11, 26 | Twyman Roy Ervin | other | 38,889 |
| Jun 11, 26 | AGUIAR-LUCANDER RENEE | other | 16,568 |
| Jun 11, 26 | AGUIAR-LUCANDER RENEE | other | 38,889 |
| Jun 11, 26 | Zuegel Martin | other | 77,778 |
| Jun 11, 26 | Zuegel Martin | other | 33,136 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ACIU coverage
Recent articles, reports, and earnings notes.
No research on ACIU yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACIU report →AC Immune to Present at Jefferies Global Healthcare Conference 2026
globenewswire.com · Nov 11
AC Immune (ACIU) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 4
AC Immune Third Quarter 2026 Financial and Corporate Update
globenewswire.com · Nov 4
Best Momentum Stock to Buy for September 30th
zacks.com · Sep 30
AC Immune Parkinson's Vaccine Study Meets Safety, Immunogenicity Goals
marketbeat.com · Sep 26
AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions
seekingalpha.com · Sep 24
AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
globenewswire.com · Sep 23
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
globenewswire.com · Aug 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.